Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 145, Issue 11, pp 2713–2723 | Cite as

A three-platelet mRNA set: MAX, MTURN and HLA-B as biomarker for lung cancer

  • Lele Liu
  • Xingguo Song
  • Xinyi Li
  • Linlin Xue
  • Shanshan Ding
  • Limin Niu
  • Li Xie
  • Xianrang SongEmail author
Original Article – Cancer Research

Abstract

Background

During the development of tumors, tumors “educate” platelets causing changes in their mRNAs expression profiles and phenotypes, thereby, tumor-educated platelet (TEP) mRNA profile has the potential to diagnose lung cancer. The current study aimed to examine whether TEPs might be a potential biomarker for lung cancer diagnostics.

Methods

Platelet precipitation was obtained by low-speed centrifugation and subjected to Trizol for total RNA extraction. Platelet MAX, MTURN, and HLA-B mRNA were selected by microarray, validated by qPCR, and analyzed combined with related clinical factors.

Results

Our results showed that a three-platelet mRNA set: MAX, MTURN, and HLA-B was significantly up-regulated in lung cancer patients as well as in early-stage lung cancer patients compared with those from healthy donors, the area under the curve (AUC) was 0.734, 0.787, respectively, among which platelet MTURN mRNA processed a dramatically high diagnostic efficiency in female patients with lung cancer, its AUC for female was 0.825. More importantly, the three-platelet mRNA set: MAX, MTURN, and HLA-B was associated with chemotherapeutic effect, low mRNA expression of this three-platelet set was correlated with “favorable” first chemotherapy response.

Conclusions

A three-platelet mRNA set: MAX, MTURN and HLA-B enables blood-based lung cancer diagnosis and chemotherapy response prediction.

Keywords

TEPs Platelet mRNA MAX MTURN HLA-B UQCRH Biomarker 

Notes

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81773237, 81672104), the Shandong Provincial Key Research and Development Program (2016GSF201211, 2016GSF201162, 2017GSF18183 and 2017CXGC1207).

Compliance with ethical standards

Conflict of interest

The authors declare that there are no conflicts of interest.

Supplementary material

432_2019_3032_MOESM1_ESM.tif (24.8 mb)
Supplementary material 1 Platelet quality control. Platelet purity was detected by wright-giemsa dye under a microscope (a), white arrow indicated the red blood cells, and activation state (b) of the platelet was detected by flow cytometry (TIFF 25418 kb)
432_2019_3032_MOESM2_ESM.tif (5.3 mb)
Supplementary material 2 Platelet UQCRH mRNA expression as biomarker for lung cancer. a Platelet UQCRH mRNA was elevated in lung cancer significantly. LC, patients with lung cancer; HD, healthy donors. b Low mRNA expression of UQCRH was correlated with favorable first chemotherapy response. PR, partial response. *P < 0.05. (TIFF 5418 kb)
432_2019_3032_MOESM3_ESM.docx (32 kb)
Supplementary material 3 (DOCX 31 kb)

References

  1. Bennett MW, O’Connell J, O’Sullivan GC, Brady C, Roche D, Collins JK et al (1998) The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160(11):5669–5675PubMedGoogle Scholar
  2. Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F et al (2015) RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28(5):666–676CrossRefGoogle Scholar
  3. Best MG, Sol N, Veld S, Vancura A, Muller M, Niemeijer AN et al (2017) Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets. Cancer Cell. 32(2):238–252CrossRefGoogle Scholar
  4. Best MG, Wesseling P, Wurdinger T (2018) Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. Cancer Res 78(13):3407–3412PubMedGoogle Scholar
  5. Blackwood EM, Luscher B, Eisenman RN (1992) Myc and max associate in vivo. Genes Dev 6(1):71–80CrossRefGoogle Scholar
  6. Boxer LM, Dang CV (2001) Translocations involving c-myc and c-myc function. Oncogene 20(40):5595–5610CrossRefGoogle Scholar
  7. Buergy D, Wenz F, Groden C, Brockmann MA (2012) Tumor-platelet interaction in solid tumors. Int J Cancer 130(12):2747–2760CrossRefGoogle Scholar
  8. Cantu de Leon D, Perez-Montiel D, Villavicencio V, Garcia Carranca A, Mohar Betancourt A, Acuna-Alonzo V et al (2009) High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study. BMC Cancer 9:48CrossRefGoogle Scholar
  9. Fervers B (2011) Chemotherapy in elderly patients with resected stage II–IIIA lung cancer. BMJ 343:d4104CrossRefGoogle Scholar
  10. Finn RS, Bengala C, Ibrahim N, Roche H, Sparano J, Strauss LC et al (2011) Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 17(21):6905–6913CrossRefGoogle Scholar
  11. Goodman RH, Smolik S (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14(13):1553–1577PubMedGoogle Scholar
  12. Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M (2013) The platelet-cancer loop. Eur J Intern Med 24(5):393–400CrossRefGoogle Scholar
  13. Goubran HA, Stakiw J, Radosevic M, Burnouf T (2014) Platelets effects on tumor growth. Semin Oncol 41(3):359–369CrossRefGoogle Scholar
  14. Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38(7):904–910CrossRefGoogle Scholar
  15. Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK (2018) The platelet lifeline to cancer: challenges and opportunities. Cancer Cell 33(6):965–983CrossRefGoogle Scholar
  16. Haghpanah V, Khalooghi K, Adabi K, Amiri P, Tavangar SM, Amirzargar A et al (2009) Associations between HLA-C alleles and papillary thyroid carcinoma. Cancer Biomark 5(1):19–22CrossRefGoogle Scholar
  17. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130CrossRefGoogle Scholar
  18. Ko HH, Lee JJ, Chen HM, Kok SH, Yen-Ping Kuo M, Cheng SJ et al (2015) Upregulation of vascular endothelial growth factor mRNA level is significantly related to progression and prognosis of oral squamous cell carcinomas. J Formos Med Assoc 114(7):605–611CrossRefGoogle Scholar
  19. Lan Q, Hsiung CA, Matsuo K, Hong YC, Seow A, Wang Z et al (2012) Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet 44(12):1330–1335CrossRefGoogle Scholar
  20. Laubli H, Borsig L (2010) Selectins promote tumor metastasis. Semin Cancer Biol 20(3):169–177CrossRefGoogle Scholar
  21. Lefrancais E, Ortiz-Munoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM et al (2017) The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature 544(7648):105–109CrossRefGoogle Scholar
  22. Leslie M (2010) Cell biology. Beyond clotting: the powers of platelets. Science 328(5978):562–564CrossRefGoogle Scholar
  23. Martinez-De Luna RI, Ku RY, Lyou Y, Zuber ME (2013) Maturin is a novel protein required for differentiation during primary neurogenesis. Dev Biol 384(1):26–40CrossRefGoogle Scholar
  24. Matowicka-Karna J, Kamocki Z, Polinska B, Osada J, Kemona H (2013) Platelets and inflammatory markers in patients with gastric cancer. Clin Dev Immunol 2013:401623CrossRefGoogle Scholar
  25. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3):328–332CrossRefGoogle Scholar
  26. Quach ME, Chen W, Li R (2018) Mechanisms of platelet clearance and translation to improve platelet storage. Blood 131(14):1512–1521CrossRefGoogle Scholar
  27. Sasaki T, Gan EC, Wakeham A, Kornbluth S, Mak TW, Okada H (2007) HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. Genes Dev 21(7):848–861CrossRefGoogle Scholar
  28. Schmidt EV (1999) The role of c-myc in cellular growth control. Oncogene 18(19):2988–2996CrossRefGoogle Scholar
  29. Sette A, Chesnut R, Fikes J (2001) HLA expression in cancer: implications for T cell-based immunotherapy. Immunogenetics 53(4):255–263CrossRefGoogle Scholar
  30. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J et al (2012) Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366(7):610–618CrossRefGoogle Scholar
  31. Sun X, Lu B, Hu B, Xiao W, Li W, Huang Z (2014) Novel function of the chromosome 7 open reading frame 41 gene to promote leukemic megakaryocyte differentiation by modulating TPA-induced signaling. Blood Cancer J 4:e198CrossRefGoogle Scholar
  32. Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M et al (2018) Platelets enhance multiple myeloma progression via IL-1beta upregulation. Clin Cancer Res 24(10):2430–2439CrossRefGoogle Scholar
  33. Torre LA, Siegel RL, Jemal A (2016) Lung cancer statistics. Adv Exp Med Biol 893:1–19CrossRefGoogle Scholar
  34. Tsukahara T, Kimura S, Ichimiya S, Torigoe T, Kawaguchi S, Wada T et al (2009) Scythe/BAT3 regulates apoptotic cell death induced by papillomavirus binding factor in human osteosarcoma. Cancer Sci 100(1):47–53CrossRefGoogle Scholar
  35. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde BJ et al (2007) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. J Immunol 178(5):2617–2621PubMedGoogle Scholar
  36. Wang R, Stone RL, Kaelber JT, Rochat RH, Nick AM, Vijayan KV et al (2015) Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer. Proc Natl Acad Sci USA 112(46):14266–14271CrossRefGoogle Scholar
  37. Wiener Z, Ontsouka EC, Jakob S, Torgler R, Falus A, Mueller C et al (2004) Synergistic induction of the Fas (CD95) ligand promoter by Max and NFkappaB in human non-small lung cancer cells. Exp Cell Res 299(1):227–235CrossRefGoogle Scholar
  38. Yi H, Xue L, Guo MX, Ma J, Zeng Y, Wang W et al (2010) Gene expression atlas for human embryogenesis. FASEB J 24(9):3341–3350CrossRefGoogle Scholar
  39. Zhou F, Zhou C (2018) Lung cancer in never smokers-the East Asian experience. Transl Lung Cancer Res 7(4):450–463CrossRefGoogle Scholar
  40. Zou P, Xia Y, Chen W, Chen X, Ying S, Feng Z et al (2016) EF24 induces ROS-mediated apoptosis via targeting thioredoxin reductase 1 in gastric cancer cells. Oncotarget 7(14):18050–18064CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.School of Medicine and Life SciencesUniversity of Jinan, Shandong Academy of Medical SciencesJinanChina
  2. 2.Department of Clinical Laboratory, Shandong Cancer Hospital and InstituteShandong First Medical University and Shandong Academy of Medical SciencesJinanChina
  3. 3.Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and InstituteShandong First Medical University and Shandong Academy of Medical SciencesJinanChina
  4. 4.Department of Clinical LaboratoryShandong Cancer Hospital Affiliated to Shandong UniversityJinanChina

Personalised recommendations